1592 -- new experimental antiretroviral. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


1592 -- new experimental antiretroviral. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.

AIDS Treat News. 1996 Aug 23;(No 253):2-3. Unique Identifier : AIDSLINE AIDS/96701860
James JS

Abstract: Glaxo Wellcome is developing a nucleoside analog which may have a stronger anti-HIV effect than other approved nucleoside analogs. In phase I/II human trials, 1592U89 (also called 1592) has already been administered to 80 volunteers with CD4 counts of 200-500 who had less than 12 weeks of prior AZT use. After 8 weeks, the patients had an average viral load reduction of about 95 to 99 percent and average CD4 count increases of 79 to 127. The manufacturers say the drug has a short half life, though it is able to cross the blood-brain barrier. Compassionate-use access may be available in the future for patients who have failed other treatment options.
Keywords: Antiviral Agents/*THERAPEUTIC USE CD4 Lymphocyte Count HIV/ISOLATION & PURIF HIV Infections/*DRUG THERAPY/IMMUNOLOGY/VIROLOGY Human NEWSLETTER ARTICLEKWDantiviralagents/KWDtherapeuticusecd4lymphocytecounthiv/isolation&purifhivinfections/KWDdrugtherapy/immunology/virologyhumannewsletterarticle
961230
M96C1438

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .